- ►umich.edu [PDF] ASF Lok - The New England Journal of Medicine, 2002 - nejm.highwire.org Insulin in the dose and regimen used in this study neither delayed nor prevented
type 1 diabetes in high-risk persons. ... Monoclonal Antibody in New-Onset Type
1 Diabetes Mellitus Mechanisms that destroy beta cells in type 1 diabetes ... Cited by 1855 - Related articles - BL Direct - All 35 versions
YF Liaw, N Leung, R Guan, GK Lau, I … - Liver Int, 2005 - heplinks.org Abstract Background/Aims: A large amount of new data on the treatment of chronic
hepatitis B has become available such that the 2003 consensus statement requires
revision and update. Methods: New data were presented, discussed and ... Cited by 270 - Related articles - View as HTML - BL Direct - All 22 versions
KM Chang, FV Chisari - Clinics in liver disease, 1999 - Elsevier The pathogenetic mechanisms responsible for the development of acute and chronic
hepatitis, cirrhosis, and HCC in patients with HBV infection are defined only
partially because of the limited host range and lack of an in vitro culture ... Cited by 102 - Related articles - BL Direct - All 9 versions
- ►annals.org [PDF] F Kanwal, IM Gralnek, P Martin, GS Dulai, M … - Annals of internal medicine, 2005 - Am Coll Physicians Background: Treatment options for chronic hepatitis B virus (HBV) infection have
disparate risks and benefits. Interferon has clinically significant side
effects, and lamivudine is associated with viral resistance. In contrast, ... Cited by 65 - Related articles - All 9 versions
- ►hivandhepatitis.com [PDF] EB Keeffe, DT Dieterich, SHB Han, IM Jacobson … - Clinical Gastroenterology and Hepatology, 2008 - Elsevier Chronic HBV infection is an important public health problem worldwide and in the
United States. A treatment algorithm for the management of this disease,
published previously by a panel of US hepatologists, has been revised on ... Cited by 64 - Related articles - All 81 versions
HLY Chan, AY Hui, VWS Wong, AML Chim, ML … - Hepatology, 2005 - interscience.wiley.com We have previously demonstrated that combination peginterferon and lamivudine
treatment has superior antiviral efficacy to lamivudine monotherapy in chronic
hepatitis B. In this study, we investigated the long-term posttreatment ... Cited by 59 - Related articles - All 4 versions
- ►yynet.cn [PDF] ASF Lok - The New England journal of medicine, 2005 - nejm.highwire.org Worldwide, there are approximately 350 million carriers of hepatitis B virus
(HBV), of whom half a million to 1 million die from liver disease each year. The
goal of treatment for chronic hepatitis B is to prevent cirrhosis, hepatic ... Cited by 58 - Related articles - All 9 versions
M Núñez, V Soriano - The Lancet Infectious Diseases, 2005 - Elsevier The management of chronic hepatitis B virus (HBV) infection poses specific
problems in the presence of HIV co-infection, since therapeutic approaches have
to consider both HBV and HIV infections. There are currently four drugs ... Cited by 54 - Related articles - All 16 versions
- ►infectshma.org.cn [PDF] RP Perrillo - Seminars in Liver Diseases, 2005 - thieme-connect.com Nucleoside analogue therapy allows safe, long-term suppression of hepatitis B
virus (HBV) and is a major milestone in the treatment of chronic hepatitis B.
Entecavir has recently been approved by the US Food and Drug Administration ... Cited by 39 - Related articles - BL Direct - All 6 versions
GV Papatheodoridis, S Manolakopoulos, G … - The Lancet Infectious Diseases, 2007 - Elsevier Currently available options for the treatment of chronic hepatitis B virus (HBV)
infection include standard and pegylated interferon alfa and four oral antiviral
agents (lamivudine, adefovir, entecavir, and telbivudine). These treatment ... Cited by 41 - Related articles - All 17 versions
